Waverley Pharma Inc. WAVE.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 221.40K | 206.50K | 213.00K | 200.10K | 278.70K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 221.40K | 206.50K | 213.00K | 200.10K | 278.70K |
| Cost of Revenue | 142.50K | 139.20K | 127.80K | 150.30K | 145.80K |
| Gross Profit | 78.90K | 67.30K | 85.20K | 49.90K | 132.90K |
| SG&A Expenses | 147.00K | 155.60K | 193.70K | 177.90K | 125.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 290.30K | 294.80K | 321.80K | 336.90K | 271.30K |
| Operating Income | -68.90K | -88.30K | -108.80K | -136.70K | 7.40K |
| Income Before Tax | -101.20K | -119.00K | -141.50K | -171.60K | -20.10K |
| Income Tax Expenses | -- | -- | 0.00 | 1.20K | -- |
| Earnings from Continuing Operations | -101.20K | -119.00K | -141.50K | -172.80K | -20.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.20K | -119.00K | -141.50K | -172.80K | -20.10K |
| EBIT | -68.90K | -88.30K | -108.80K | -136.70K | 7.40K |
| EBITDA | -54.40K | -73.60K | -98.40K | -121.80K | 22.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 54.00M | 54.00M | 54.00M | 54.00M | 54.00M |
| Average Diluted Shares Outstanding | 54.00M | 54.00M | 54.00M | 54.00M | 54.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |